SNHG25: A Small Nucleolar RNA Host Gene 25 (G105376843)

Target Name: SNHG25

NCBI ID: G105376843

SNHG25

Other Name(s): small nucleolar RNA host gene 25 | Small nucleolar RNA host gene 25

SNHG25: A Small Nucleolar RNA Host Gene 25

Introduction

Small nucleolar RNA (snRNA) host genes are a class of non-coding RNAs that play a crucial role in the regulation of gene expression in eukaryotic organisms. These genes are expressed in high abundance in the nucleolus, which is the functional unit of the nucleus responsible for the production of RNA. One of the key functions of snRNAs is to act as a scaffold to recruit other RNA molecules to the transcribing mRNA, thereby ensuring the accuracy and efficiency of gene expression.

SNHG25, a member of the SNHG gene family, is a SNRNA host gene that has been identified as a potential drug target and biomarker. In this article, we will provide an overview of SNHG25, including its structure, function, and potential clinical applications.

Structure and Function

SNHG25 is a 21-kb RNA molecule that contains 11 unique exons and an additional exon that is highly conserved across different species. The exons are organized into three domains: the first domain includes a 5'-end cap structure, the second domain includes a 3'-end cap structure, and the third domain includes a unique 5'-end region that is highly conserved across different species.

The function of SNHG25 is to act as a scaffold to recruit other RNA molecules to the transcribing mRNA. Through the binding and pairing mechanism, SNHG25 can recognize and bind to specific promoter regions on mRNA, thereby ensuring smooth transcription of mRNA. In addition, SNHG25 can also bind and pair other types of RNA molecules, such as small nuclear RNA (snRNA) and non-coding RNA (ncRNA), thus playing a broader regulatory role.

The protein product of SNHG25 includes a 190-amino-acid protein molecule and a 510-base pair RNA molecule. Protein molecules are composed of two subunits, each subunit contains a core ?±-helix and two ??-helices. RNA molecules contain a 5'-end cap structure and three 3'-end cap structures.

The expression level of the SNHG25 gene varies in different species, such as higher expression levels in humans and lower expression levels in mice. Knockdown of SNHG25 results in RNAi silencing, resulting in a decrease in gene expression levels. In addition, knockdown of SNHG25 can also lead to changes in chromatin structure, such as chromatin condensation and nucleosome formation, thereby affecting the regulation of gene expression.

Pharmacological significance of SNHG25

SNHG25 is a very promising drug target because it is closely related to the occurrence and development of various cancers. Many studies have shown that knockdown of SNHG25 is associated with the progression of various cancers. For example, knockdown of SNHG25 is associated with the progression and enhanced invasiveness of cancers such as lung cancer, liver cancer, and breast cancer.

In addition, SNHG25 is also related to the function of immune cells. SNHG25 can bind to MHC molecules in immune cells, thereby participating in immune cell recognition and memory. Therefore, knockdown of SNHG25 may affect the function of the immune system, thereby increasing the immune evasion ability of tumors.

Detection and diagnosis of SNHG25

The detection and diagnosis of SNHG25 is an important issue in cancer diagnosis and treatment. At present, the detection of SNHG25 mainly includes two aspects: gene expression level and protein level.

Detection of gene expression levels can be achieved through RNAi technology, which can detect the knockdown effect of SNHG25 by silencing SNHG25 with RNAi. Through RNAi experiments, we can

Protein Name: Small Nucleolar RNA Host Gene 25

The "SNHG25 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNHG25 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets